PharmaDepth

Company profile

Phathom Pharmaceuticals, Inc.

NASDAQ:PHATBiotechnology: Pharmaceutical Preparations

Drug pipeline (3)

AssetStageRevenueTrialsStatus
Amoxicillinapproved—14approved
Clarithromycinapproved—11approved
Vonoprazan Fumaratephase3—26no active trials

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (14)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT06851559phase2active_not_recruiting2025-10-302026-10-01Phathom Pharmaceuticals, Inc.A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
NCT05366738phase1completed2022-05-182022-07-01Phathom Pharmaceuticals, Inc.A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants
NCT06831344phase1completed2025-02-142025-04-05Phathom Pharmaceuticals, Inc.A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants
NCT06391177phase1completed2024-05-072024-09-13Phathom Pharmaceuticals, Inc.A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily
NCT06106022phase1completed2023-11-012024-04-16Phathom Pharmaceuticals, Inc.A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease

FDA applications (4)

ApplicationTypeApplicantProducts
NDA 215151NDAPHATHOM PHARMACEUTICALS INC
NDA 215152NDAPHATHOM PHARMACEUTICALS INC
NDA 215153NDAPHATHOM PHARMACEUTICALS INC
NDA 218710NDAPHATHOM PHARMACEUTICALS INC